ASH 2017 | Best treatment strategy for FLT3 ITD AML
Keith Pratz
• 9 Dec 2017
FLT3 ITD acute myeloid leukemia (AML) is associated with high rates of relapse, after which prognosis is very poor. Thus, the improvement of initial therapy for this group of patients is crucial. In this interview, Keith Pratz, MD, of Johns Hopkins University, Baltimore, MD, discusses the results of a study investigating the outcomes of patients with FLT3 ITD AML, in order to identify which treatment strategies lead to the most favorable outcomes. Factors considered included the role of chemotherapy (cytarabine), targeted agents (TKIs) and MRD status pre- and post-transplant. This video was recorded at the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA.
